VGF and SCG2 also showed a decrease in CSF in AD patients [75,76], so among the potential biomarkers, only PDYN seems to remain unchanged in AD (no publications have been able to show any variation in the CSF levels of AD patients). This evidence concerns the gene SCG2 and Alzheimer disease.